Predictors of Thromboembolic Events in Patients with Lung Cancer

KADLEC, Bohdan a Jana SKŘIČKOVÁ. Predictors of Thromboembolic Events in Patients with Lung Cancer. In 16th World Conference on Lung Cancer. 2015. ISSN 1556-0864.

Základní údaje

• Originální název: Predictors of Thromboembolic Events in Patients with Lung Cancer
• Autoři: KADLEC, Bohdan (203 Česká republika, domácí) a Jana SKŘIČKOVÁ (203 Česká republika, garant, domácí).
• Vydání: 16th World Conference on Lung Cancer, 2015.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Konferenční abstrakt
• Obor: 30203 Respiratory systems
• Stát vydavatele: Spojené státy
• Utajení: není předmětem státního či obchodního tajemství
• Impakt faktor: Impact factor: 5.040
• Kód RIV: RIV/00216224:14110/15:00084851
• Organizační jednotka: Lékařská fakulta
• ISSN: 1556-0864
• Klíčová slova anglicky: VTE; lung cancer; thrombosis; incidence; predictors
• Štítky: EL OK

Anotace

Background: Patients with lung cancer experience elevated risk of venous thromboembolism Prothrombotic factors in lung cancer include the ability of tumour cells to produce and secrete procoagulant substances and inflammatory cytokines, and the physical interaction between tumour cell and blood. Other mechanisms of thrombus promotion in malignancy include surgery, metastatic disease and use of chemotherapeutic drugs in combination with novel targeted drugs, such as antiangiogenic agents. Cancer patients with thrombosis have a shorter life expectancy than cancer patients without this complication. The occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. Conclusion: The incidence of serious thromboembolic events (8.4%) in our group of lung cancer patients was high, especially in patients with adenocarcinoma, advanced-stage disease, and in patiens on cancer treatment. In patients with thromboembolic disease, significantly higher median platelet counts were observed at the time of cancer diagnosis. In patients treated with chemotherapy, most thromboembolic events were observed shortly after the treatment starts and the majority of thromboembolic events occurred within 6 months after the initiation of chemotherapy. These results justify prophylactic treatment in most patients with advanced or metastatic disease, adenocarcinoma, patients receiving radiotherapy or chemotherapy, and in presence of some associated disorders.